Updated ARAF published for women prescribed Sodium Valproate(Epilim)
As part of the continuing efforts to reduce the risks associated with the anti-seizure medication, Sodium Valproate (Epilim), the Health Products Regulatory Authority (HPRA) have recently reissued patient information materials and reminders to prescribers and pharmacists about their obligations under the Pregnancy Prevention Programme (PPP) and risk reduction measures associated with the medication.